GoodRx Holdings Inc-A 2025年季度报告

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ______ to ______.Commission File Number:001-39549________________________________GoodRx Holdings, Inc.(Exact Name of Registrant as Specified in its Charter)________________________________ Delaware(State or other jurisdiction ofincorporation or organization) company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.Large accelerated fileroAccelerated filerx Non-accelerated filero oEmerging growth companyoIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNox As ofApril29, 2025, the registranthad100,300,165shares of Class A common stock, $0.0001 par value per share, and256,869,320shares of Class B common stock, $0.0001 par value per share, outstanding. FORWARD-LOOKING STATEMENTS forward-looking statements largely on our current expectations and projections about future events and financial trends thatwe believe may affect our business, financial condition and results of operations. Forward-looking statements involve knownandunknown risks,uncertainties and other important factors that may cause our actual results,performance or growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad marketeducation and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our and adversely affect our results of operations; risks related to the healthcare reform legislation and other proposed or futurechanges impacting the healthcare industry and healthcare spending which may adversely affect our business, financial our Annual Report on Form 10-K for the fiscal year endedDecember31, 2024(“202410-K”) and this Quarterly Report onForm 10-Q for the three months ended March 31, 2025,and in our other filings with the Securities and ExchangeCommission (“SEC”). The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all ofour forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any Table of Contents forward-looking statements contained in this Quarterly Report on Form 10-Q, whether as a result of any new information,future events or otherwise. We periodically post information that may be important to investors on our investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complyingwith our disclosure obligations under Regulation FD.Accordingly,investors and potential investors areencouraged to consult our website regularly for important information, in addition to following GoodRx’s press releases, through, our website is not incorporated by reference into, and is not a part of, this Quarterly Report on Form 10-Q. Table of Contents Table of Contents Page PART I.FINANCIAL INFORMATIONItem 1.Financial Statements1 Condensed Consolidated Statements of Operations Condensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash Flows Notes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations Quantitative and Qualitative Disclosures About Market Risk Item 1.Item 1A. Risk Factors Item 3.Defaults Upon Senior Securities23Item 4.Mine Safety Disclosures23Item 5.Other Information23 (in thousands, except par values)AssetsCurrent assetsCash and cash equivalentsAccounts receivable, netPrepaid expenses and other current assetsTotal current assetsProperty and equipment, netGoodwillIntangible assets, netCapitalized software, netOperating lease right-of-use assets, net Deferred tax assets, netOther assets Total assetsLiabilities and stockholders' equityCurrent liabilitiesAccounts payableAccrued expenses and other current liabilities Cash flows from investing activitiesPurchase of property and equipment(142)(407) Use of EstimatesThe preparation of the condensed consolidated financial statements in conformity with GAAP requires management tomake estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements, Table of Contents including the accompanying